Editorial: TSH Receptor and Autoimmunity
- Thyroid Research Unit, The Mount Sinai Medical Center and the James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Editorial on the Research Topic
TSH Receptor and Autoimmunity
Over time it has become clear that the fascination with the TSH receptor (TSHR) is not only its complexity and its relationship to human disease but the fact that it keeps teaching us fundamental biology at all levels; cellular, molecular, and genetic. There are good examples of each of these facets in this cutting edge collection of papers. This contribution provides a brief and broad overview highlighting those areas of active progress by briefly eluding to some of the contributions in this collection.
The TSHR is a member of the class A family of G-protein coupled receptors (GPCR) with seven transmembrane helices traversing the plasma membrane and a large extracellular ectodomain. The ectodomain (ECD) is linked to a distal signal-specific domain—the hinge region—which is attached to a transmembrane domain (TMD) consisting of extracellular (ECL) and intracellular (ICL) loops (Figure 1). A partial TSHR ectodomain (residues 1–260) has been crystallized either bound to a stimulating TSHR antibody and/or a blocking TSHR antibody (1, 5) and recently in an unbound native state with stabilizing mutations. Like other GPCRs, the TSH receptor can also not exist in an ensemble of conformational states which can lead to its varied signaling potential. The review by Kleinau et al. in this collection takes a comprehensive look at the structure-function relationship of the TSHR via modeling and mutational approaches. It is now well-known that the full-length TSHR undergoes complex post translational processing (6, 7) inclusive of common protein modifications such as glycosylation and phosphorylation and even whole receptor modifications such as cleavage and multimerization (7, 8) thus resulting in a surprising variety of receptor configurations, many of which are expressed on the cell surface (9) and in some cases even shed from the cell surface (10). Although the shed receptor forms have not been conclusively demonstrated in the serum of patients with Graves' disease (GD), probably secondary to degradation, the evidence that these and other receptor structures are critical to the immunopathogenesis of GD has been well-covered in the review by Inaba et al.
Figure 1. Homology model of the entire TSH holoreceptor. This model highlights the tripartite structure of the TSHR. The ectodomain, shown in gray/black, is made up of 10 leucine-rich repeat domains (LRD) characterized as a “scythe-blade” shaped structure with loops and β pleated sheets obtained from the published crystal structure (1) (PDB:3G04). The region connecting the LRD and transmembrane domain (TMD), known as the “hinge” region, has recently been crystallized for the FSH receptor (2) (PDB:4AY9) and is shown as a looped structure (orange) with a helix conformation close to the carboxyl end of the LRD. The hinge in the TSHR has an additional sequence insert and is larger than in the FSH receptor. Therefore, amino acids 305-381 are missing in the illustrated model (3) and this insert is depicted as a closed dotted loop. The TMD (yellow), with its seven helices, is depicted as cylindrical structures connected to each other by the specific TSHR intra and extracellular loops. The TMD is the region that harbors the allosteric binding pockets for the SMLs. LRD, leucine-rich domain; TMD, transmembrane domain; ECL, extracellular loops; and ICL, intracellular loops [Figure adapted from (4)].
Signal transduction at the TSHR is complex because of the promiscuous nature of the TSHR in engaging with different G proteins (11). In addition, the TSHR signals can be both G protein dependent and G protein independent. The TSHR has been shown to engage predominantly β-arrestin-2 for internalization (12) and arrestin-1, in human osteoblast cells, for differentiation, and MAP kinase signaling (13). In addition, it has long been known that the TSHR is involved with the IGF1/insulin receptor in thyroid cells and the “marriage” of these two receptors in fibroblasts has suggested their involvement in Graves' eye disease pathophysiology as well-reviewed by Smith et al.. The complex life cycle of GPCRs such as the TSHR (Figure 2) has also begun to be revealed showing that these types of GPCRs, after being sequestered via clathrin-coated pits or caveolin scaffolding proteins, are still able to signal after internalization. New evidence points out that these internalized receptors can lead to a “second wave” of signals from the TSHR (14). The result is that not only does the receptor come in multiple configurations but there are also multiple signal pathways that may or may not be initiated as the receptor conformation changes on ligand binding and this may continue after the receptors are internalized. The days of thinking simply of the TSH induced cyclic AMP response coming only from the surface receptors have long gone. Single-particle electron microscopy has confirmed the presence of intracellular megaplexes which consist of a GPCR bound to β-arrestin at its C terminus and a G protein complex at its core (15). The crystallization of a GPCR bound to G proteins has enhanced our understanding that ligands can stabilize different receptor conformations and that these ligand bound receptor complexes can stabilize different effector conformations leading to diversified signaling. However, such full-length receptor and G protein crystallized conformation(s) have not yet been achieved for the TSHR.
Figure 2. Generic life-cycle of the TSH receptor. The TSHR residing on the plasma membrane of thyrocytes on binding with its cognate ligand, TSH, is activated and in turn undergoes conformational changes to recruit and activate a G protein complex leading to a predominate wave of Gs generated cAMP (Signal 1). The activated receptor, after signal 1, is phosphorylated and then moved to clathrin-coated pits where β-arrestin is bound to the activated receptor. At this stage it is believed that the receptor can signal via arrestin leading to β-arrestin-associated signals. Furthermore, this activated receptor in the invaginated pits is pinched-off to form the early and late endosomes. It is described that within the endosome the receptor with its associated ligand and second messengers is capable of giving out a second wave cAMP signal (Signal 2). Following this the receptor can be either degraded or it enters recycling vesicles and is recycled to the plasma membrane whereas the ligand is transported to the lysosome and is degraded. This is the life that the TSHR lives on the surface of thyrocytes or any other cell where it is expressed.
The TSHR can be activated by TSH itself, or by autoantibodies which can bind to the orthosteric site(s) on the large ectodomain. In fact, activation of the TSHR has been in clinical use for many years. Semi-purified bovine TSH was originally used for short-term thyroid testing of TSHR function but proved to have too many immune related side effects in clinical practice. The clinical use of TSH was not widely adopted until the introduction of recombinant human TSH in the 1990's. This is now used for detecting thyroglobulin release from metastatic thyroid cancer and for enhancing RAI uptake into thyroid glands (16–18). The discovery of stimulating TSHR antibodies by Adams and Purves (19) demonstrated the cause of Graves' disease and helped open up the entire field of autoimmune disease. Since the discovery of TSHR autoantibodies there has been the development of clinical assays to effectively detect these antibodies in Graves' patients with improving accuracy and sensitivity. The reviews by Giuliani et al. tracing the development of TSH bioassays and by Kahaly et al. on functionality and nomenclature are interesting and important in this regard. Although the current assays for detecting these antibodies are relatively robust the solid phase assays cannot detect bioactivity and the cell based bioassays are also not ideal where high concentrations of blocking antibodies may decrease the TSHR response to stimulating antibodies. Such problems arise due to the plethora of antibodies with variable bioactivities seen in GD indicative of a wide spectrum of variable activities as discussed further below.
In recent years it been shown by several investigators that selected small molecule ligands (SML) can easily permeate the plasma membrane and allosterically activate or inhibit TSHR signals. High throughput functional screening methods led to their identification and has opened up new therapeutic potentials (20–22). Furthermore, the concept that various effectors can stabilize the TSHR in a particular conformation has opened the possibility of biased TSHR signaling as achieved with other GPCR's (23, 24).
A major clinical need is for potent TSHR antagonists that can block the TSHR antibodies of hyperthyroid Graves' disease allowing us to dispense with the side effects of the common antithyroid drugs (methimazole and PTU) which deter many physicians from their long term use. A blocking human monoclonal TSHR antibody has been proposed as one method of achieving this aim (25) and results of a Phase II clinical trial are awaited. Although therapeutic antibodies have the theoretical advantage of specificity so do potential small molecule TSHR antagonists. Several groups, including our own laboratory as described by Latif et al. included in this collection (26, 27), have shown that allosteric inhibition of TSHR G protein signaling can silence the TSHR receptor. However, low potency and inadequate specificity of these SML antagonists indicate that more hurdles have to be crossed for the advancement of this approach. Peptide mimetics and aptamers to the TSHR that can either disrupt signaling via preventing G protein binding or by interfering with TSHR antigen processing are also under development and in early stage clinical trials and further data are awaited.
At long last it is becoming widely known that the TSHR is expressed in more places than the thyroid gland and can even be found to be expressed in embryonic stem cells suggesting a role in development (11). The TSHR is expressed in fibroblasts, adipocytes, bone cells, and a variety of additional cell types (28, 29) and have, in particular, attracted a lot of attention in the retro-orbit (30–32) and bone (33, 34). This ubiquitous presence of the receptor clearly suggests that it has more functions than controlling thyroid hormone production. The role of TSHR activation and its signaling influence on adipocytes has been studied (35) and activation of the TSHR can modulate adipogenesis and fat cell phenotype further reinforced in the article by Draman et al.. The role of the TSHR in differentiation of preadipocytes into mature adipocytes from embryonic stem cells has also been shown (36) although the signals that influence this differentiation pathway are still unclear. The “Graves' Disease Triad” consists of hyperthyroidism with a dermopathy, referred to as pre-tibial myxedema, and an orbitopathy often referred to as Graves' Eye Disease and involves fibroblasts and adipocytes at both extra-thyroidal sites. Retro-orbital expression of the TSHR, in combination with IGF-1 receptors (37), expressed on the fibroblasts and adipocytes behind the eye appear to be involved in the pathogenesis of Graves' orbitopathy GO- (see Smith et al.) and serum TSHR-Ab levels tend to correlate with eye disease (38–40). IGF-1 is well-known to enhance TSH action on thyroid cells and recent studies show that blockade of the IGF-1R appears to be a useful mode of therapy for GO (41, 42) presumably by reducing stimulating TSHR-Ab-induced adipocyte proliferation and cytokine release from retro-orbital fibroblasts. Such cytokines contribute to glycosaminoglycan generation and disrupt the osmotic pressure behind the eyes causing muscle fiber damage and swelling (42, 43). Similarly, our work on TSHR expression in osteoblasts and osteoclasts has identified TSH as a potential osteoprotective molecule (33). The identification of a TSH-β subunit splice variant secreted by bone marrow macrophages may be the effector of this protective effect as discussed in detail by Baliram et al. (44).
One of the unique characteristics of Graves' disease, not found in normal individuals or in the rest of the animal kingdom, is the presence of TSHR antibodies (TSHR-Ab) which are easily detectable in the vast majority of patients as discussed earlier (45). In such patients, TSHR-reactive T cells and B cells survive central and peripheral deletion and under appropriate circumstances the B cells secrete TSHR antibodies and also induce T cells to secrete pro-inflammatory cytokines (46). Hence both B cells and T cells play a central role in mediating the chronic inflammatory changes of the autoimmune diseases seen in the thyroid gland, in the retro-orbit and in the skin (19), and may be resistant to T regulatory cell (Treg) control or allowed to be active secondary to inadequate Treg function (47). Although TSHR autoantibodies represent the hallmark of GD, finding the triggers that lead to this immunological derangement has been a challenge. Genome-wide association studies have established the association of the TSHR gene specifically with GD and understanding the functional mechanism by which such polymorphisms modify the physiological processes and trigger disease by interfering with central tolerance is outlined in the review by Stefan et al.. Whatever may be the major mechanisms for these triggers we now see three varieties of TSHR-Ab that can be found in patients with autoimmune thyroid disease and in TSHR immunized rodents; stimulating, blocking, and so called “neutral” antibodies; the latter often directed at the hinge region of the TSHR ectodomain and are far from being neutral in their biological activity. Stimulating antibodies induce cyclic AMP, thyroid cell proliferation and thyroid hormone synthesis, and secretion. They bind exclusively to conformational epitopes in the TSHR ectodomain leucine rich repeat region and compete with TSH for binding. TSHR blocking antibodies compete with TSH for binding and once bound they inhibit TSH action to a variable extent. However, the degree of blocking may be profound enough that they may induce hypothyroidism although some blocking TSHR antibodies may actually behave as weak TSHR agonists. In contrast, the neutral TSHR antibodies neither block TSH binding nor block TSH action but may be involved in aberrant signal initiation and thyroid cell apoptosis (48, 49). It is important to also remember that TSHR antibodies have an important role to play in pregnancy because these antibodies cross the placenta and influence both maternal and fetal thyroid function and their biochemical and immunological aspects are well-dealt with by Bucci et al..
Apoptosis in Graves' Disease
It is now apparent that apoptosis plays an important role in the development and perpetuation of autoimmune thyroid disease. Areas of apoptosis are recognized in thyroid tissue from patients with Hashimoto's Thyroiditis and Graves' disease (50). Subsequent studies on apoptosis have provided insight into autoimmune target destruction, indicating the involvement of death receptors and cytokine-regulated apoptotic pathways in the pathogenesis, and perpetuation of thyroid autoimmunity. There is evidence that such thyrocyte apoptosis in Graves' disease may be antibody induced (51) or T cell mediated via defects in T regulatory cells which induce an abnormal production of cytokines (52) or changes in the expression of apoptotic molecules (Fas/FasL and caspase 8) on the surface of T lymphocytes and thyroid follicular cells (53, 54). In fact, all antibody binding to the thyroid cell induces thyroid cell stress, as first shown by our own laboratory, but we have shown that some neutral antibodies induce excessive ROS accumulation leading to thyroid cell apoptosis in the absence of G-protein signaling (49, 55, 56). This antibody induced apoptosis can facilitate the breakdown of self- tolerance mechanisms in individuals with the right major histocompatibility complex (MHC) class II background in myriad ways. It could be the release of excessive cytosolic DNA fragments that can act as adjuvants/immune modulators and induce aberrant MHC II expression in thyrocytes thus inducing the release of multiple inflammatory cytokines and chemokines as seen in various animal models and well-reviewed by Luo et al. in this collection.
The Multiplicity of TSH Receptor Forms and Responses May Explain the Graves' Disease Phenotype
With the initial discovery of the classical G-protein–coupled-receptors (GPCR) the essential mechanisms appeared at first to be straightforward. The ectodomain was responsible for hormone specificity and the intracellular domain was responsible for the cyclic AMP signal. Each receptor had a specific ligand and an expected action. The receptor for TSH was very similar to that for FSH and LH/hCG and each activated PKA and the cyclic AMP pathway. Such simplicity, however, was short lived. Firstly, the TSHR was found to have two unique inserts into the ectodomain, including one which made it subject to complex post translational processing not seen with the LHR and FSHR. Then the phenomenon of specificity cross-over reared its head. Suddenly the concept of high specificity of a hormone receptor was in doubt. For example, a number of ligands are able to bind to and activate the TSHR including hCG and LH. Stimulation of the TSHR by hCG is seen in gestational thyrotoxicosis (57) and in choriocarcinoma and a unique TSHR mutation even more highly hCG reactive has been described. With the burgeoning of our understanding into the structure of the TSHR by comparative modeling and partial crystal structures the entire field of TSHR signal transduction opened up. TSH/hCG and small molecule agonists could initiate different signals depending on the concentration of ligand available for receptor binding, the number of receptors activated, the forms of receptor (dimeric vs. monomeric) and also the orthosteric vs. the allosteric sites. Hence, we have the issue of multiple specificities and multiple signal responses indicating that an enormous number of variables are at play at just one GPCR. If we then consider Graves' disease and its multiple clinical forms which can vary from a highly localized thyroid disease to almost a systemic autoimmune diathesis much of this may be explicable by the variable forms of the receptor available for immune activation, the variable sites of TSHR expression and the multiplicity of signals that the TSHR can employ. In addition, the presence of differing proportions of high affinity TSHR-Abs with varied biological activity in patients with GD no doubt also contributes to the multiple clinical phenotypes; varying from hyperthyroidism to hypothyroidism and vice versa and with or without Graves' orbitopathy and pre-tibial myxedema.
The collection of papers that form part of this special issue shows the different facets of the TSHR thus allowing us to rightly say that many roads lead from and to this GPCR. For sure the TSHR, with its structural and signaling complexity, is going to hold our scientific imagination and enthusiasm for many more years to come.
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
This work was supported by NIH grant DK069713, a VA Merit Award BX000800 (to TD) and the David Owen Segal Endowment.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The handling Editor declared a shared affiliation, though no other collaboration with the authors.
1. Sanders J, Chirgadze DY, Sanders P, Baker S, Sullivan A, Bhardwaja A, et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid (2007) 17:395–410. doi: 10.1089/thy.2007.0034
2. Jiang X, Liu H, Chen X, Chen PH, Fischer D, Sriraman V, et al. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor. Proc Natl Acad Sci USA. (2012) 109:12491–6. doi: 10.1073/pnas.1206643109
3. Krause G, Kreuchwig A, Kleinau G. Extended and structurally supported insights into extracellular hormone binding, signal transduction and organization of the thyrotropin receptor. PLoS ONE (2012) 7:e52920. doi: 10.1371/journal.pone.0052920
5. Sanders P, Young S, Sanders J, Kabelis K, Baker S, Sullivan A, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. (2011) 46:81–99. doi: 10.1530/JME-10-0127
7. Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am. (2009) 38:319–41, doi: 10.1016/j.ecl.2009.01.006
8. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, Gales C, et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. (2005) 24:1954–64. doi: 10.1038/sj.emboj.7600686
10. Quellari M, Desroches A, Beau I, Beaudeux E, Misrahi M. Role of cleavage and shedding in human thyrotropin receptor function and trafficking. Eur J Biochem. (2003) 270:3486–97. doi: 10.1046/j.1432-1033.2003.03718.x
14. Godbole A, Lyga S, Lohse MJ, Calebiro D. Internalized TSH receptors en route to the TGN induce local Gs-protein signaling and gene transcription. Nat Commun. (2017) 8:443. doi: 10.1038/s41467-017-00357-2
16. Huber GK, Fong P, Concepcion ES, Davies TF. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab. (1991) 72:1328–31. doi: 10.1210/jcem-72-6-1328
17. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. (1997) 337:888–96. doi: 10.1056/NEJM199709253371304
18. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. (2002) 87:1490–8. doi: 10.1210/jcem.87.4.8338
20. Neumann S, Kleinau G, Costanzi S, Moore S, Jiang JK, Raaka BM, et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology (2008) 149:5945–50. doi: 10.1210/en.2008-0836
24. Landomiel F, Gallay N, Jegot G, Tranchant T, Durand G, Bourquard T, et al. Biased signalling in follicle stimulating hormone action. Mol Cell Endocrinol. (2014) 382:452–9. doi: 10.1016/j.mce.2013.09.035
26. Neumann S, Nir EA, Eliseeva E, Huang W, Marugan J, Xiao J, et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology (2014) 155:310–4. doi: 10.1210/en.2013-1835
29. Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc Natl Acad Sci USA. (2002) 99:15776–81. doi: 10.1073/pnas.242322099
32. Gershengorn MC, Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS. A drug-like antagonist inhibits TSH receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid (2012) 22:839–43. doi: 10.1089/thy.2011.0520
35. Elgadi A, Zemack H, Marcus C, Norgren S. Tissue-specific knockout of TSHr in white adipose tissue increases adipocyte size and decreases TSH-induced lipolysis. Biochem Biophys Res Commun. (2010) 393:526–30. doi: 10.1016/j.bbrc.2010.02.042
39. Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol. (2011) 46:155–63. doi: 10.1530/JME-11-0006
40. Kumar S, Schiefer R, Coenen MJ, Bahn RS. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts. Thyroid (2010) 20:59–65. doi: 10.1089/thy.2009.0278
44. Baliram R, Chow A, Huber AK, Collier L, Ali MR, Morshed SA, et al. Thyroid and bone: macrophage-derived TSH-beta splice variant increases murine osteoblastogenesis. Endocrinology (2013) 154:4919–26. doi: 10.1210/en.2012-2234
45. Vlase H, Davies TF. Insights into the molecular mechanisms of the autoimmune thyroid diseases. In: Eisenbarth GS editor. Endocrine and Organ Specific Autoimmunity. R.G. Landes Co (1999). p. 98–132.
46. Bagriacik EU, Klein JR. The thyrotropin (thyroid-stimulating hormone) receptor is expressed on murine dendritic cells and on a subset of CD45RBhigh lymph node T cells: functional role for thyroid-stimulating hormone during immune activation. J Immunol. (2000) 164:6158–65. doi: 10.4049/jimmunol.164.12.6158
49. Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology (2010) 151:5537–49. doi: 10.1210/en.2010-0424
52. Mao C, Wang S, Xiao Y, Xu J, Jiang Q, Jin M, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol. (2011) 186:4734–43. doi: 10.4049/jimmunol.0904135
53. Bossowski A, Czarnocka B, Bardadin K, Stasiak-Barmuta A, Urban M, Dadan J, et al. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Autoimmunity (2008) 41:163–73. doi: 10.1080/08916930701727749
54. Bossowski A, Czarnocka B, Bardadin K, Urban M, Niedziela M, Dadan J. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases. Horm Res. (2008) 70:155–64. doi: 10.1159/000145017
Keywords: TSHR (thyroid-stimulating hormone receptor), GPCR (G-protein-coupled receptors), autoantibodies, TSH (thyroid stimulating hormone), small molecule
Citation: Davies TF and Latif R (2019) Editorial: TSH Receptor and Autoimmunity. Front. Endocrinol. 10:19. doi: 10.3389/fendo.2019.00019
Received: 24 December 2018; Accepted: 14 January 2019;
Published: 30 January 2019.
Edited and reviewed by: Derek LeRoith, Icahn School of Medicine at Mount Sinai, United States
Copyright © 2019 Davies and Latif. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Terry F. Davies, firstname.lastname@example.org